Adapt Pharma announced that it has received FDA approval for a 2 mg dose version of Narcan naloxone nasal spray for the treatment of opioid overdose for opioid-addicted patients who would likely experience severe withdrawal if given the 4 mg dose.
The 4 mg per dose formulation of Narcan was approved by the FDA in November 2015, and Adapt launched the nasal spray in the US in February 2016.
Read the Adapt Pharma press release.
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
